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Background
Ipilimumab, an anti-CTLA-4 monoclonal antibody, is
approved for treatment of unresectable/metastatic mela-
noma[1]. Treatment benefits only a subset of patients (pts)
and is associated with significant adverse effects. Biomar-
kers of pt response are needed. Single cell network profil-
ing (SCNP) is a multiparametric flow cytometry-based
assay that quantitatively measures both phenotypic mar-
kers and changes in intracellular signaling proteins in
response to modulation, enabling analysis of cell signaling
networks[2,3]. We have been concerned on functional
proteomic profiling of immune signaling pathways in
PBMC subsets in healthy donors and pts with metastatic
melanoma receiving ipilumumab treatment.
Methods
3 healthy and 13 melanoma pt cryopreserved samples,
(7 pre-treatment (pre-Tx), 6 post-treatment (post-Tx))
were analyzed. Cells were assessed for viability, cell subset
frequencies and signaling in response to modulation. A
node is the combination of modulator and intracellular
readout (e.g. IL-6 -> p-STAT3). Cytokine, TCR- or FcgR-
induced activation of STAT1, 3, 5, CD3z and Erk was
evaluated in immune cell populations and comparisons
made based on disease, treatment time point and clinical
responses.
Results
Compared to healthy, melanoma monocytes displayed
lower IL-10®p-STAT1, IL-10®p-STAT3, IL-6®
p-STAT1, IL-6®p-STAT3 and FcgR®p-Erk. Similarly,
TCR®p-CD3 was reduced most prominently in
CD45RA- CD4+ and CD4- T cells. These data suggest
hyporesponsivity of circulating immune cell subsets in the
innate and adaptive arms of the immune response in mel-
anoma pts. The same observations pertained to melanoma
samples independent from administration of, or clinical
response to, treatment. Effects of treatment on T cell sig-
naling were observed compared to healthy donors and
pre-Tx samples. Post-Tx samples had diminished
TCR®p-Erk, TCR®p-CD3z in CD4+ and CD4- more
prominently in CD45RA+ than CD45RA- subsets and
diminished IL-15®p-STAT5 in CD4- T cells. No markers
associated with clinical response to ipilumumab. In sam-
ples from non-responsive pts, the level of basal p-Erk in
CD45RA+ CD4+ T cells and the percentage of Treg was
higher compared to those of complete responders and
healthy donors.
Conclusions
SCNP analysis of PBMC from healthy donors and mela-
noma pts pre-Tx and post-Tx identified signaling differ-
ences between melanoma and healthy and between
pre- and post-Tx. Candidate predictive biomarkers for
patient stratification will be evaluated in subsequent larger
studies.* Correspondence: drew.hotson@nodality.com
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